Revolutionary new drug set to be available on NHS cuts risk of fatal epileptic seizures
The once-a-day pill, to be available on the NHS, helps prevent the most dangerous seizures, which leave patients unconscious and can lead to serious injury or sudden death.
The worst affected can have dozens of fits a month, usually without warning, so many are afraid to go out and can't socialise normally. Some even lose their jobs.
A revolutionary new drug that can significantly reduce their number of potentially fatal epileptic seizures is to made available on the NHS
But an international trial of the drug Perampanel found 23 per cent of those taking it stopped having such seizures completely. A further 64 per cent saw seizures cut by more than half.
The drug will cost the NHS £5 a day per patient – about £1,800 a year.
Glasgow University's Professor Martin Brodie, director of the Epilepsy Unit at the city's Western Infirmary, said: 'This lets people get on with their lives and relax, without worrying whether the next seizure means breaking bones or ending up in hospital.
'Their quality of life hugely improves. The results from the trial are encouraging, but I would expect the drug to perform even better in the real world, because a wider range of people will have access to it.'
Epilepsy affects about 600,000 people in the UK.
The drug is licensed for those with genetic epilepsy (around a third of sufferers) who also experience the most serious seizures, known as primary generalised tonic-clonic, or PGTC.
These increase the risk of sudden unexplained death in epilepsy, which is linked to some 1,000 deaths in the UK every year. It is estimated that about 91,000 people fall into this category.
Perampanel, manufactured by Eisai, targets a new mechanism in the brain to prevent cells from becoming overexcited.
Epilepsy sufferers can have dozens of fits a month, usually without warning, so many are afraid to go out and can't socialise normally. Some even lose their jobs
It has been available for those with partial-onset seizures since 2012, which means that NHS organisations are already able to prescribe it.
Scott Barclay, 34, from Glasgow, lost his job as a financial adviser after suffering seizures in front of clients.
He had up to 15 fits a day and ended up in a wheelchair after one left him with a broken back. But since taking Perampanel he averages a seizure a month.
Mr Barclay said: 'My life has changed completely. I can go out by myself and be at home by myself, travel and socialise. For the first time, I can be an adult.'
- Once-a-day pill, costing £5, helps prevent the most dangerous seizures
- Trial found 23% of those taking it stopped having such seizures completely
- Epilepsy affects about 600,000 people in the UK and fits can cause serious injury or sudden death
The once-a-day pill, to be available on the NHS, helps prevent the most dangerous seizures, which leave patients unconscious and can lead to serious injury or sudden death.
The worst affected can have dozens of fits a month, usually without warning, so many are afraid to go out and can't socialise normally. Some even lose their jobs.
A revolutionary new drug that can significantly reduce their number of potentially fatal epileptic seizures is to made available on the NHS
But an international trial of the drug Perampanel found 23 per cent of those taking it stopped having such seizures completely. A further 64 per cent saw seizures cut by more than half.
The drug will cost the NHS £5 a day per patient – about £1,800 a year.
Glasgow University's Professor Martin Brodie, director of the Epilepsy Unit at the city's Western Infirmary, said: 'This lets people get on with their lives and relax, without worrying whether the next seizure means breaking bones or ending up in hospital.
'Their quality of life hugely improves. The results from the trial are encouraging, but I would expect the drug to perform even better in the real world, because a wider range of people will have access to it.'
Epilepsy affects about 600,000 people in the UK.
The drug is licensed for those with genetic epilepsy (around a third of sufferers) who also experience the most serious seizures, known as primary generalised tonic-clonic, or PGTC.
These increase the risk of sudden unexplained death in epilepsy, which is linked to some 1,000 deaths in the UK every year. It is estimated that about 91,000 people fall into this category.
Perampanel, manufactured by Eisai, targets a new mechanism in the brain to prevent cells from becoming overexcited.
Epilepsy sufferers can have dozens of fits a month, usually without warning, so many are afraid to go out and can't socialise normally. Some even lose their jobs
It has been available for those with partial-onset seizures since 2012, which means that NHS organisations are already able to prescribe it.
Scott Barclay, 34, from Glasgow, lost his job as a financial adviser after suffering seizures in front of clients.
He had up to 15 fits a day and ended up in a wheelchair after one left him with a broken back. But since taking Perampanel he averages a seizure a month.
Mr Barclay said: 'My life has changed completely. I can go out by myself and be at home by myself, travel and socialise. For the first time, I can be an adult.'